What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination

“…Moreover, the role of low-density lipoprotein cholesterol (LDL-C) in the pathophysiology of CHD is acknowledged and wellunderstood, and the use of LDL-C-lowering medications has led to a significant reduction of cardiovascular risk in both primary and secondary prevention. Therefore, LDL-C is recommended as the primary treatment target for lipid management in many guidelines, such as the US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines [6], the 2012 Japan Atherosclerosis Society (JAS) guidelines [7], the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, the 2014/2015 National Lipid Association (NLA) recommendations for management of dyslipidemia in the context of evolving evidence [8], the 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines [9], and the 2016 Chinese guidelines for the management of adult dyslipidemia (revised edition) [10].…”

Innovative Approaches to Teaching Dyslipidemia Management in a Required Pharmacy Therapeutics Sequence

“…2,3 To adequately prepare students to care for patients with dyslipidemia in clinical practice, pharmacy education should ideally include a context of the historical treatment approach based on the National Cholesterol Education Panel's Adult Treatment Panel III and updated (2001 and 2004) guidelines, the ACC/AHA 2013 Blood Cholesterol guidelines, and the NLA recommendations. [1][2][3][4][5][6][7][8][9][10] This amount of content requires significant didactic and active learning time, and traditional teaching approaches may not allow students to truly achieve the ability to provide patient-centered care as described by the Center for Advancement of Pharmacy Education's Educational Outcome (CAPE) 2.1. 11 Additionally, the 2016 Accreditation Council for Pharmacy Education (ACPE) Standards require a greater focus on active learning pedagogy that allows learners to apply information to practical situations.…”

Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

“…Neither guideline addressed the 2015 introduction of the proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) or the new evidence on CV outcomes using ezetimibe in combination with a statin. [6][7][8][9] Therefore, in fall 2015, the ACC convened a group of health care practitioners and stakeholders, including (but not limited to) representation from the NLA, patient advocacy groups, managed care groups, and drug manufacturers, in a meeting denoted as "LDL: Address the Risk Think Tank" to expand recommendations that addressed the full spectrum of dyslipidemia treatment. A smaller writing group used information from that meeting to produce the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, intended to serve as a bridge from the current 2013 guidelines to the update expected in 2017.…”